We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Hematology-Oncology

ATG Versus ATG Plus Post-Transplant Cyclophosphamide: A Pilot Trial for GvHD Prophylaxis in Matched Donor Hematopoietic Cell Transplants

MedXY Editorial Team•Aug 24, 2026•Hematology-Oncology
Bệnh Graft-versus-Hostanti-thymocyte globulinhematopoietic cell transplantposttransplant cyclophosphamide

Highlight

This randomized pilot trial from the Cell Therapy Transplant Canada and Australasian Leukemia Lymphoma Group Consortium compared anti-thymocyte globulin (ATG) alone to ATG combined with post-transplant cyclophosphamide (PTCy) in matched donor hematopoietic cell transplantation (HCT) for patients with AML and MDS. The combination regimen demonstrated comparable 100-day overall survival, relapse, and non-relapse mortality rates versus ATG alone, with manageable safety profiles, supporting feasibility for phase III trials.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

ATG versus Alemtuzumab for GvHD Prophylaxis in AML Allo-HCT: Insights from the EBMT RegistryIn AML patients undergoing unrelated donor allo-HCT with intermediate-intensity conditioning, ATG-based GvHD prophylaxis demonstrated better overall and leukemia-free survival and reduced relapse compared to alemtuzumab, despite higher acutSep 17, 2026Optimizing GVHD Prophylaxis after Reduced-Intensity Matched Donor Transplantation in AML and MDS: Insights from PTCy and ATG StrategiesA large registry analysis supports post-transplant cyclophosphamide (PTCy) as an effective alternative to anti-thymocyte globulin (ATG) for preventing graft-versus-host disease (GVHD) in reduced-intensity conditioning matched donor peripherSep 17, 2026Impact of Induction Course Number on Outcomes of Allogeneic Stem Cell Transplant with Post-Transplant Cyclophosphamide in AMLThis study compares outcomes after allogeneic stem cell transplantation using post-transplant cyclophosphamide in AML patients achieving first remission with one versus two induction courses, revealing similar survival but higher relapse wiSep 12, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Early Inflammatory Complications After Pediatric Haploidentical HSCT with Post-Transplant Cyclophosphamide: Clinical Impact and Risk Factors
This multicenter study identifies peripheral blood stem cell use as a key risk factor for early inflammatory complications post-haploidentical HSCT in children, linking these events to refractory acute and chronic graft-versus-host disease.
Aug 11, 2026
CHIME: A Novel HLA Eplet Model Predicting Non-Relapse Mortality in Haploidentical Hematopoietic Cell TransplantationThis study introduces CHIME, a novel HLA eplet mismatch model, revealing its association with non-relapse mortality and severe aGvHD in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide, improving Jul 9, 2026
Unified Conditioning and GVHD Prophylaxis with Fludarabine, Cyclophosphamide, and 2 Gy TBI plus Post-Transplant Cyclophosphamide in Elderly AML/MDS Patients Undergoing Haploidentical or Unrelated Donor Allo-SCTFludarabine, cyclophosphamide, and low-dose TBI combined with post-transplant cyclophosphamide provide a safe and effective single platform for haploidentical and unrelated donor allo-SCT in older AML/MDS patients, showing favorable survivaJun 30, 2026